SCH-900105 in Recurrent Glioblastoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01189513|
Recruitment Status : Withdrawn (Sponsor decision.)
First Posted : August 26, 2010
Last Update Posted : February 20, 2012
|Condition or disease||Intervention/treatment||Phase|
|Glioblastoma||Drug: SCH 900105||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Evaluation of SCH 900105 With Correlative Tissue Studies in the Treatment of Adult Patients With Recurrent Glioblastoma|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||January 2011|
|Actual Study Completion Date :||January 2011|
Experimental: SCH 900105
10 mg/kg intravenous Days 1, 8 and 15 of 30 day cycle.
Drug: SCH 900105
10 mg/kg by vein every week on days 1, 8 and 15 of a 30 day cycle.
- Maximum Tolerated Dose (MTD) [ Time Frame: 30 days for Cycle 1, and every 28 days for following cycles ]MTD of SCH 900105 defined as the dose level prior to that resulting in dose limiting toxicity (DLT i.e., the dose level at which no more than 1 out of 6 subjects experiences). DLT).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01189513
|Principal Investigator:||John DeGroot, MD||UT MD Anderson Cancer Center|